HK2 can act as a protein kinase and phosphorylate IκBα at T291, leading to NF-κB-dependent upregulation of PD-L1 expression, which suppresses CD8 T cell activation and infiltration into tumor tissues, accelerating brain tumor growth and increasing resistance to immune checkpoint blockade therapy. This evidence concerns the gene HK2 and neoplasm.